Bangladesh DGDA Registered Medical Devices Teardown: Chinese IVDs & Class C Majority
A data-driven teardown of Bangladesh's Directorate General of Drug Administration (DGDA) registered medical device list, analyzing risk classes, manufacturers, and importers.
Market Sourcing in South Asia's Emerging MedTech Giant
Bangladesh represents one of the fastest-growing healthcare markets in South Asia, driven by a population of over 170 million, rising middle-class disposable income, and a concerted push to modernize public and private hospital networks. Historically, the medical device sector in Bangladesh operated with minimal regulatory oversight. However, the introduction of the Drug and Cosmetics Act 2023 (effective September 18, 2023) changed this landscape, making registration mandatory for all medical devices, including software and raw materials. For foreign manufacturers, navigating this import-dependent market requires a clear understanding of the active registry and the commercial channels that control it.
Scenario Question:
We are scoping Bangladesh for device launch — what is registered today, which classes dominate, and which local importers and foreign manufacturers already hold share?
Direct Answer:
The Directorate General of Drug Administration (DGDA) registered medical device list contains 4,268 unique device listings as of July 2026. Class C (moderate-to-high risk) is the largest category, accounting for 1,380 listings (32.3%), followed closely by Class A (low risk, 1,321, 30.9%), Class B (low-to-moderate risk, 1,154, 27.0%), and Class D (high risk, 405, 9.5%). Sourcing is heavily led by Chinese in vitro diagnostics (IVD) manufacturers (such as Shenzhen YHLO Biotech and Snibe) and Western cardiovascular and ophthalmic giants (including Boston Scientific, Medtronic, GE Healthcare, and Carl Zeiss Meditec). A small group of Dhaka-based importers — led by ABC Corporation and Medtronic Bangladesh — concentrate the majority of registrations, functioning as key market gatekeepers.
This teardown provides a comprehensive, data-driven analysis of Bangladesh’s registered medical device list, breaks down the risk classes and manufacturer concentration, maps the key local importers, and details the compliance requirements of the 2023 Drug and Cosmetics Act.
How many medical devices are registered with DGDA, and how do the A-D classes split?
The Directorate General of Drug Administration (DGDA) regulates all medical devices, diagnostics, and pharmaceuticals in Bangladesh under the Ministry of Health and Family Welfare. To map the active device listings, we analyzed the consolidated registered medical device database.
As of the July 6, 2026 export, the registry contains 4,268 active medical device registrations. The classification of these devices follows a four-tier risk structure (Class A to D), which is aligned with the ASEAN Medical Device Directive (AMDD) and GHTF classification principles.
The table below illustrates the risk-class distribution of registered devices in Bangladesh:
| Risk Class | Risk Profile | Equivalent EU Class | Registered Devices | Share of Register (%) |
|---|---|---|---|---|
| Class A | Low Risk | Class I (non-sterile, non-measuring) | 1,321 | 30.95% |
| Class B | Low-to-Moderate Risk | Class I (sterile/measuring), Class IIa | 1,154 | 27.04% |
| Class C | Moderate-to-High Risk | Class IIb | 1,380 | 32.33% |
| Class D | High Risk | Class III | 405 | 9.49% |
| Total | 4,268 | 100.00% |
Risk Class Breakdown:
- Class C (1,380 devices, 32.3%): Surprisingly, Class C represents the largest single category. This is driven by the volume of diagnostic reagents, specialized clinical consumables (such as hemodialyzers, blood lines, and catheters), and complex surgical drapes. Because each clinical assay kit or catheter length requires an individual registration, these product lines dominate the list.
- Class A (1,321 devices, 30.9%): This represents low-risk devices such as adhesive bandages, clinical furniture, manual surgical instruments, and basic labware. The high number reflects a backlog of legacy Class A approvals registered between 2011 and 2025.
- Class B (1,154 devices, 27.0%): Includes moderate-risk items like standard syringes, blood pressure monitors, examination gloves, and basic diagnostic kits.
- Class D (405 devices, 9.5%): The highest-risk category, consisting of implantable pacemakers, coronary stents, orthopedic joint replacements, and high-risk IVD assays (such as HIV and Hepatitis screening kits).
Which foreign manufacturers dominate the Bangladesh register?
Bangladesh is highly dependent on imports, with industry estimates (e.g., Pure Global) putting foreign supply at roughly 85% of the country's medical devices. The registry is highly concentrated, with a small number of global suppliers holding a disproportionate share of registrations.
The table below ranks the top foreign manufacturers by their number of active registrations in the DGDA database:
| Manufacturer | Country of Origin | Active Registrations | Primary Product Category |
|---|---|---|---|
| Hilbro Pvt Ltd | Pakistan | 86 | Reusable surgical instruments (Sialkot cluster) |
| Shenzhen YHLO Biotech | China | 46 | IVD immunoassay reagents and analyzers |
| Snibe / Shenzhen New Industries | China | 45 | Chemiluminescence immunoassay (CLIA) reagents |
| Lohmann & Rauscher | Germany / Austria | 28 | Wound dressings, compression bandages |
| Boston Scientific Corp | United States | 24 | Coronary stents, angioplasty catheters |
| BioSystems S.A. | Spain | 23 | Clinical chemistry reagents, control kits |
| Carl Zeiss Meditec | Germany | 20 | Ophthalmic diagnostic and surgical microscopes |
Key Sourcing Patterns:
- The Chinese IVD Footprint: Chinese manufacturers have established a dominant position in the diagnostics sector. Shenzhen YHLO Biotech and Snibe hold a combined 91 active registrations, reflecting their success in placing automated clinical analyzers and reagents in diagnostic laboratories across Dhaka and Chittagong.
- Pakistan Surgical Supplies: Hilbro Pvt Ltd leads the manufacturer list with 86 active registrations. These represent manual surgical instruments manufactured in the Sialkot cluster. This is consistent with sourcing patterns observed in other emerging registries, where reusable steel instruments require a high number of individual product listings.
- US Cardiovascular Innovation: Boston Scientific and Medtronic represent the high-value segment, with registrations focusing on interventional cardiology, cardiac rhythm management, and vascular therapy.
Which local importers concentrate the most DGDA registrations?
A critical feature of the Bangladeshi medical device market is the role of local importers. Under DGDA rules, a foreign manufacturer cannot register a device directly. Registrations must be submitted by a local sponsor holding a valid Drug Import License (DIL), who becomes the legal holder of the registration certificate (the DAR number).
Because the local importer holds the registration, they function as gatekeepers. Changing importers requires a formal "No Objection Certificate" (NOC) from the current holder, creating a commercial lock-in effect.
The table below lists the top local importers holding active DGDA medical device registrations:
| Local Importer (Dhaka-based) | Active Registrations | Core Portfolio |
|---|---|---|
| ABC Corporation | 93 | Cardiovascular, diagnostics, surgical supplies |
| Medtronic Bangladesh Pvt Ltd | 91 | Dedicated Medtronic cardiovascular & neurovascular |
| Boi-Trade International | 45 | Reagents, clinical laboratory kits, IVD analyzers |
| GE Healthcare Bangladesh | 43 | Diagnostic imaging, CT, MRI, ultrasound systems |
Importer Concentration Dynamics:
- Commercial Lock-In: The top four importers above each hold dozens of registrations, and the long tail of Dhaka importers holds the remainder. For foreign companies, selecting a local representative is a critical decision. If a partnership sours, the importer holds the DAR number, which can block the manufacturer from importing products through other channels unless the importer signs an NOC.
- Dedicated Subsidiaries: To mitigate this risk, larger multinationals have established local legal entities (such as Medtronic Bangladesh) to hold their registrations directly, giving them full control over their distribution channels.
What does the registered mix reveal about Bangladesh's device market structure?
The DGDA registry provides a clear snapshot of an emerging, import-dependent device market. Sourcing split is structurally polarized between two primary categories:
Sourcing Channel Splitting in Bangladesh
| Segment | Risk Profile / Class | Primary Product Lines | Dominant Sourcing Region |
|---|---|---|---|
| Premium Clinical Hardware | Class C & D | Coronary stents, pacemakers, ophthalmic lasers, diagnostic imaging (CT/MRI) | United States, Germany, Japan |
| Commodity Lab / Consumables | Class A & B | IVD reagents, assays, clinical drapes, syringes, reusable surgical instruments | China, India, Pakistan (Sialkot) |
- Premium Capital and Implants: The premium market is dominated by US, German, and Japanese brands, focusing on diagnostic imaging (GE, Siemens), ophthalmology (Zeiss), and interventional cardiology (Boston Scientific, Medtronic). Sourcing is driven by clinical preference and technical complexity.
- Diagnostics and Consumables: The high-volume laboratory segment is contested by Chinese and European IVD manufacturers, leveraging lower cost structures to secure hospital lab contracts. Reusable steel drapes and forceps remain dominated by Pakistani suppliers.
Bangladesh in the South Asian Regulatory Context
Bangladesh's DGDA framework shares the broad shape of its South Asian neighbors but differs in the specifics that matter to market-access teams. Across the region — India (CDSCO), Pakistan (DRAP), Sri Lanka (NMRA), and Bangladesh (DGDA) — a foreign manufacturer must appoint a local representative who is legally responsible for the registration, and all four systems use a risk-based A–D (or equivalent) classification aligned with GHTF/ASEAN principles. What sets Bangladesh apart is operational rather than structural: the embassy-attested Free Sale Certificate is a particularly strict gate (the FSC must be legalized by the Bangladesh Embassy in the issuing country), and the registration is held by the local importer rather than the manufacturer. For a side-by-side regulatory comparison with neighboring Pakistan, see our Pakistan DRAP registration guide; the data teardown for that market is our Pakistan DRAP registered devices teardown.
The Drug and Cosmetics Act 2023: Key Regulatory Shifts
The Drug and Cosmetics Act 2023, signed into law on September 18, 2023, replaced the outdated Drugs Act of 1940. This legislation represents a complete overhaul of the medical product regulatory framework in Bangladesh.
Grace Periods and Transition Timelines
Following the implementation of the Act on September 18, 2023, the DGDA applied transitional arrangements for products already present on the market:
- Transitional Window for Legacy Devices: Manufacturers and local importers of previously unregulated devices were given a defined grace period to compile and submit their applications for risk classification and registration. Confirm the current status of any remaining transition rules with the DGDA, as enforcement timelines have been phased in over the period since enactment.
- Post-Transition Enforcement: Unregistered devices found in commercial circulation after the transition window are subject to seizure, and distributors and importers may face penalties under the Act's enforcement provisions.
- Manufacturing Site Audits: Local manufacturing facilities were given a transitional period to align with WHO GMP-type standards before the DGDA initiated mandatory licensing inspections.
Major Legislative Changes:
- Explicit Device Definitions: For the first time, medical devices, diagnostic reagents, and software are defined as "drugs" under the scope of the Act, giving the DGDA clear enforcement power over their manufacturing, import, and sale.
- Establishment Licensing: All local device manufacturing facilities, warehouses, and distribution offices must obtain specific establishment licenses from the DGDA, subject to compliance audits.
- Strict Penalty Framework: The Act introduces significant penalties — including imprisonment and substantial fines — for importing or distributing unregistered, counterfeit, or misbranded devices. Refer to the current Act text for the specific penalty provisions applicable to a given offence.
- Adverse Event Reporting: Manufacturers and their local sponsors are legally required to report any device-related adverse events or recalls to the DGDA within designated timelines.
Step-by-Step Registration Workflow Comparison
Navigating the DGDA registration process varies depending on the risk class of the device. The table below compares the workflow steps and documentation requirements across the risk classes:
| Process Step | Class A (Low Risk) | Class B, C, and D (Mod-to-High Risk) |
|---|---|---|
| 1. Local Sponsor Mandate | Assign local importer with valid DIL. | Assign local importer with valid DIL. |
| 2. Dossier Preparation | Basic QMS certificate, ISO 13485. | Complete ASEAN CSDT (Common Submission Dossier Template). |
| 3. Embassies Attestation | Not required. | Free Sale Certificate (FSC) must be attested by Bangladesh Embassy. |
| 4. Technical Review | Fast-track administrative check. | Technical Committee evaluation (clinical data and QMS review). |
| 5. License Issuance | Listing entry (no DAR number). | DAR (Drug Registration Number) issued, valid for 5 years. |
| 6. Processing Timeline | 10 to 15 business days. | 30 to 40 days (official), 3 to 6 months (actual). |
Importer Selection Checklist for Foreign MedTech Companies
To manage the DAR registration lock-in risk, foreign manufacturers should evaluate potential Bangladeshi importers using the following criteria:
- Valid Licenses: Does the importer hold an active Drug Import License (DIL) and Trade License?
- Regulatory Capabilities: Does the importer have a dedicated regulatory affairs team experienced in compiling the ASEAN CSDT dossier?
- Embassy Relations: Are they experienced in managing the embassy attestation process for Free Sale Certificates?
- Distribution Reach: Do they have direct distribution channels to major public and private hospitals (e.g., Dhaka Medical College Hospital, Evercare Hospital)?
- Contractual Flexibility: Will they agree to a contract clause requiring them to transfer or release the DAR registration (via a No Objection Certificate) to a secondary representative if distribution performance targets are not met?
- Cold-Chain and Storage Capability: Does the importer maintain temperature-controlled, audited storage for reagents and temperature-sensitive IVD products?
- Post-Market Vigilance Support: Can the importer support recall management and report serious adverse events to the DGDA within the mandatory 48-hour (fatal) and 10-day (serious injury) windows?
DGDA Medical Device Fee Schedule
Government fees for medical device registration are paid in local currency (BDT). Under the two-step process used for Class B, C, and D devices, registration practitioners and consultancy sources (Asia Actual; registration-practitioner reports) cite a total government fee on the order of BDT 63,250 (~US$540–600) per product, including VAT, spread across the evaluation and license-issuance steps, with no government fee for Class A notifications and official processing targeted at roughly 30–40 days once a file is complete (3–6 months in practice).
| Application Type | Indicative Government Fee | Notes |
|---|---|---|
| Class A Notification | No government fee | Listing route; certificate does not expire |
| Class B / C / D Registration | ~BDT 63,250 (~US$540–600) per product, incl. VAT | Two-step (Recipe Approval + Final Registration); registration valid 5 years |
Fee basis: secondary consultancy and practitioner figures. DGDA fee schedules are set by rule and re-fixed periodically, so confirm the current schedule on the official DGDA site before budgeting.
Beyond Government Fees: Testing and Consultation
In addition to the official DGDA application charges, manufacturers should budget for secondary costs:
- Local Laboratory Testing: For some Class C and D devices (particularly active systems or novel sterile implants), the Technical Committee may require sample testing at a designated local institute (such as the National Control Laboratory), focusing on sterility, biocompatibility, or electrical safety. Cost and lead time vary by product family and should be confirmed with the evaluator.
- Consulting Fees: Local regulatory consultants in Dhaka commonly manage the submission, compile the ASEAN CSDT, and interface with the evaluation committees; fees vary by dossier complexity and importer arrangement.
Procurement Channels in Bangladesh: Public vs. Private Markets
Understanding the registered-device mix requires analyzing the two distinct purchasing channels in Bangladesh's healthcare system.
1. The Public Procurement Sector
The public sector is funded by the national budget and managed by the Central Medical Stores Depot (CMSD) under the Directorate General of Health Services (DGHS).
- Tendering Process: Procurement is conducted through open international competitive bidding (tenders).
- Registration Gate: Holding an active DGDA registration and DAR number is a mandatory prerequisite to bid.
- Sourcing Focus: Public tenders favor lower-cost systems, opening market opportunities for Chinese and Indian manufacturers who hold registered portfolios in Class B/C reagents and basic clinical hardware.
2. The Private Procurement Sector
The private sector consists of premium corporate hospitals (such as Evercare Hospital, Square Hospitals, and United Hospital) and diagnostic laboratory chains.
- Purchase Method: Private hospitals purchase directly from authorized distributors.
- Sourcing Focus: Clinical teams favor systems with USFDA clearance or CE marking. Private facilities are willing to pay a premium for Western brands (such as GE, Siemens, Medtronic, and Boston Scientific) to support their diagnostic and surgical reputations.
Frequently Asked Questions
Does DGDA classify devices the same way as the EU or ASEAN?
Yes, DGDA uses a four-class risk structure (Class A, B, C, and D) that is aligned with the ASEAN Medical Device Directive (AMDD). Class A represents the lowest risk (similar to EU Class I), and Class D represents the highest risk (similar to EU Class III). However, DGDA retains the right to classify specific devices differently based on local clinical concerns, particularly for combination products and software.
Which device categories are most registered in Bangladesh?
The registry is dominated by in vitro diagnostic (IVD) reagents and assay kits (Class C) and reusable manual surgical instruments (Class A). This reflects the high number of individual part numbers required to support laboratory diagnostic panels and general surgery instrument sets.
Can a foreign manufacturer register directly, or is a local importer required?
A foreign manufacturer cannot register a device directly with the DGDA. They must appoint a local agent registered in Bangladesh who holds a Drug Import License. This local agent submits the registration files and holds the DAR number.
Does DGDA require local laboratory testing for all medical devices?
No, DGDA does not require local testing for all medical devices. It is typically reserved for Class C and D products, or when the evaluation committee has questions about the manufacturer's sterility validation or biocompatibility data. For Class A and B devices with reputable clearances (e.g. US FDA or CE marking), local testing is almost always waived. When local testing is required, it must be performed at an approved government lab (such as the National Control Laboratory) and can add 30-60 days to the process.
What are the language requirements for Bangladesh submissions?
The primary language for all registration files is English. Technical documentation (such as GMS/QMS certificates, clinical data, and ASEAN CSDT) must be in English. For patient-facing materials, such as user manuals, labeling, and patient guides, the DGDA strongly encourages bilingual labeling (English and Bengali) to ensure safety and usability among patients in domestic clinical environments.
Can a foreign manufacturer use multiple importers in Bangladesh?
Yes, a foreign manufacturer can theoretically appoint multiple importers, but each importer must submit a separate registration and obtain a separate DAR number for the product. This means that if you import the same device through three different distributors, each must hold a DAR number linked to their Drug Import License. This duplicates registration fees and administrative effort. The recommended practice is to appoint a single regulatory representative (such as a consultant or dedicated local entity) to hold the registration DAR numbers, and authorize multiple commercial distributors to import against that single registration.
Strategic Recommendations for Market Entry
For MedTech commercial and regulatory teams entering Bangladesh, the data points to several key strategies:
- Strategic Representative Selection: Because the local importer holds the registration, perform due diligence before appointing a local sponsor. Ensure they have the capabilities to manage both imports and regulatory changes.
- Dossier Authentication: Ensure the Free Sale Certificate (FSC) is issued by an approved reference jurisdiction (US, EU, Japan, Australia, or Singapore) and is attested by the Bangladesh Embassy in that country, as this is a strict gatekeeping requirement.
- IVD Market Strategy: For diagnostics companies, expect pricing competition from Chinese CLIA and immunoassay manufacturers, who hold a strong share of the registrations.
For comparisons with neighboring South Asian regulatory frameworks, review the Pakistan DRAP registration guide. For a broader look at regional market-access strategy, see the Asia-Pacific registration strategy. For a sibling data teardown, refer to the Cuba CECMED registry teardown.
Disclaimer: This analysis is based on data extracted from the Directorate General of Drug Administration (DGDA) registered medical device database as of July 6, 2026. Regulatory policies and fee structures are subject to change. Manufacturers should consult with qualified local regulatory experts before initiating submissions.